Sabra MM, et al. - In patients presenting with lung metastasis from radioactive iodine refractory progressive thyroid cancer, researchers evaluated molecular targeted therapy (MTT)’s ability to affect tumour volume doubling time (TVDT) and disease-specific survival (DSS). According to this retrospective study, the median survival after MTT started was 2.9 years. Investigators observed a prolonged lung average tumor volume doubling time (midDT) ≥ 3 years in 75% of cases with baseline midDT ≤ 1 year and 100% of patients with midDT 1-3 years. In patients with rapidly progressive thyroid cancer, they found the median survival of 4.5 years in those with MTT-achieved midDT ≥3 years, as compared to 2.3 years and 0.7 years in those with MTT-achieved midDT of 1-3 years and MTT-achieved midDT ≤1 year respectively. In patients with progressive radioactive iodine refractory (RAIR) metastatic thyroid cancer, lung midDT is a useful and important clinical marker of disease-specific survival. Data reported that molecular targeted therapy prolongs lung tumour volume doubling time and was related to improved disease-specific survival in patients with rapidly progressive metastatic RAIR thyroid cancer.